Research Team Discovers Key Gene For Telomerase Enzyme In Humans

August 13, 1997

Researchers from the University of Colorado at Boulder and Geron Corp. have discovered the human gene for the active component of an enzyme known as telomerase that lengthens the ends of chromosomes, a finding that may lead to improved cancer diagnosis and treatment.

The end portions of chromosomes, called telomeres, contain repeating sequences of DNA that protect the chromosomes from damage, said Toru Nakamura, a CU-Boulder researcher, Howard Hughes Medical Institute scientist and lead author on the study. Since portions of the telomeres are lost each time a cell divides, telomere shortening is thought to act as a molecular clock of sorts by signaling the cell to stop dividing after repeated cell divisions.

But the telomerase enzyme counteracts telomere shortening by adding DNA back onto the chromosome ends, he said. Normal cells do not contain telomerase, and their telomeres shorten with each cell division until they stop dividing. In cancer cells, however, telomerase is thought to grant the cell immortality by maintaining telomere length so that the cell never receives a signal to stop dividing.

"Correlation of telomerase activity and cancer has been shown previously, but there has been little evidence for a causal relationship between the two," said Nakamura. "Having the human telomerase gene may aid in testing the relationship."

The discovery of the gene for the protein called Telomerase Reverse Transcriptase is reported in the Aug. 15 issue of Science.

Authors of the Science paper include Nakamura, Joachim Lingner and Thomas Cech of CU-Boulder and the Howard Hughes Medical Institute, and Gregg Morin, Karen Chapman, Scott Weinrich, William Andrews and Calvin Harley of Geron Corp. of Menlo Park, Calif.

Before the discovery of the telomerase gene, "Cancer researchers knew telomerase only indirectly, by following the reaction it catalyzed," said Cech, who shared the 1989 Nobel prize for chemistry. "Now we have the ability to make lots of pure telomerase to understand its properties and learn how to inhibit it."

The team cloned telomerase genes in two evolutionarily diverse species, yeast and humans. The genes were found to be similar, indicating telomerase was first developed by an ancient organism and subsequently inherited by all eukaryotes -- organisms whose cells have a separate nucleus and cytoplasm, including humans.

"It means that studies on simple organisms like yeast are relevant to the human enzyme," said Cech. Telomerase contains both RNA and protein components. The RNA portion of the enzyme binds to the DNA in the telomere while the protein component lures DNA subunits into the region and attaches them to the end of the chromosome. "The protein we describe in our paper forms a complex with the telomerase RNA and does the job of telomeric DNA synthesis," said Nakamura.

Telomerase belongs to a class of enzymes known as reverse transcriptases that use RNA as a template for creating DNA. Retroviruses like HIV also belong to this class. Since reverse transcriptases share a common amino acid sequence, they are expected to have similar three-dimensional structures. This indicates that variants of "inhibitors such as AZT developed for treatment of AIDs may be able to inhibit telomerase," Nakamura said.

Many researchers believe telomerase's most promising application may be in diagnosing cancer. By developing ways to detect telomerase activity in cells, it may be possible to diagnose cancer before palpable tumors have formed.

But Nakamura urges caution in heralding telomerase as the newest cure for cancer. "Nothing has been shown to work yet," he said.
-end-


University of Colorado at Boulder

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.